TY - JOUR
T1 - Subacute lack of asthma control and acute asthma exacerbation history as predictors of subsequent acute asthma exacerbations
T2 - Evidence from managed care data
AU - O'Connor, Richard D.
AU - Bleecker, Eugene R.
AU - Long, Aidan
AU - Tashkin, Donald
AU - Peters, Stephen
AU - Klingman, David
AU - Gutierrez, Benjamin
N1 - Funding Information:
Funding for the study was provided by AstraZeneca LP, Wilmington, DE. The authors thank Keith Brown from the University of North Carolina—General Administration, Chapel Hill, NC; Chakkarin Burudpakdee, Jonothan Tierce, and Julie Munakata from IMS Heath, Inc., Falls Church, VA; Bhash Parasuraman from AstraZeneca LP, Wilmington, DE; and Robert Boggs from Wyeth, Collegeville, PA (formerly of AstraZeneca LP), for their contributions to this study.
Funding Information:
Richard O’Connor has no relevant financial interests in this manuscript. Eugene Bleecker has served as a consultant for AstraZeneca, Boehringer-Ingelheim, Centocor, Genen-tech, GalxoSmithKline, Novartis, Pfizer, Wyeth, and Merck and has received research grants for clinical trials during the last 5 years through Wake Forest University Health Sciences, Aerovance, Amgen, AstraZeneca, Boehringer-Ingelheim, Centocor, Ception, Genentech, GlaxoSmith-Kline, Novartis, Pfizer, and Wyeth. Aidan Long has received a research grant from Genentech, has served as a consultant for sanofi-aventis, was PST for Genentech, and is on the Board of Directors for Asthma and Allergy Foundation of America – New England Chapter. Donald Tashkin has served as consultant and speaker for and has received research grants from AstraZeneca. Stephen Peters has served as consultant and speaker for AstraZeneca. David Kling-man has had contracts with IMS for Abbott, Amgen, Forest, GlaxoSmithKline, Medtronic, Merck, Novo Nordisk, Pfizer, sanofiaventis, Shire, Vertex, and Wyeth. Benjamin Gutierrez was an employee of AstraZeneca at the time of the manuscript authorship.
PY - 2010/5
Y1 - 2010/5
N2 - Background. Monitoring indicators of subacute lack of asthma control (SALAC) may help to reduce asthma morbidity. Objective. To determine whether SALAC, independent of current asthma exacerbations, is associated with subsequent acute asthma exacerbations. Methods. Administrative claims data from PharMetrics/IMS Health were used to identify patients 12 years or older continuously enrolled in a participating U.S. health plan from 2001 to 2004 with ≥1 asthma claim (International Classification of Diseases, Ninth Revision, Clinical Modification code 493.x), no chronic obstructive pulmonary disease or cystic fibrosis claims, and ≥1 prescription for an asthma medication during 20012004. SALAC was defined as more than 4 asthma-related physician visits (or ≥2/quarter) or more than 5 short-acting β2-adrenergic agonist prescriptions during 2001. Effect of asthma control category (Exacerbation Only EO, SALAC Only SO, Both Exacerbation and SALAC Both, Neither Exacerbation nor SALAC Neither) in 2001 on acute asthma exacerbations (hospitalization, emergency department visit, or short-term oral corticosteroid use) during 20022004 was assessed using logistic regression, adjusting for gender, age, health plan type, and region. Results. Of 11,779 patients, 8 were assigned to the EO group, 26 to SO, 12 to Both, and 54 to Neither in 2001. The incidence of exacerbations in 20022004 was higher for Both (61.8) versus EO (55.0) and for SO (37.3) versus Neither (31.9). The risk of exacerbation in 20022004 was increased significantly (p < .0001) for Both (3.394; 95 confidence interval CI 3.009, 3.827), EO (2.503; 95 CI 2.176, 2.879), and SO (1.277; 95 CI 1.166, 1.399) versus Neither. Conclusion. In this study, the risk of subsequent exacerbation was greatest in patients with both SALAC and acute asthma exacerbations, followed by those with exacerbations only and those with SALAC only. SO identified an additional 26 of asthma patients at increased risk for subsequent exacerbation. The results from this study demonstrate that SALAC indicators and a history of acute asthma exacerbations are independent predictors of future acute asthma exacerbations and highlight the important role of subacute asthma worsening in predicting and preventing future asthma exacerbations.
AB - Background. Monitoring indicators of subacute lack of asthma control (SALAC) may help to reduce asthma morbidity. Objective. To determine whether SALAC, independent of current asthma exacerbations, is associated with subsequent acute asthma exacerbations. Methods. Administrative claims data from PharMetrics/IMS Health were used to identify patients 12 years or older continuously enrolled in a participating U.S. health plan from 2001 to 2004 with ≥1 asthma claim (International Classification of Diseases, Ninth Revision, Clinical Modification code 493.x), no chronic obstructive pulmonary disease or cystic fibrosis claims, and ≥1 prescription for an asthma medication during 20012004. SALAC was defined as more than 4 asthma-related physician visits (or ≥2/quarter) or more than 5 short-acting β2-adrenergic agonist prescriptions during 2001. Effect of asthma control category (Exacerbation Only EO, SALAC Only SO, Both Exacerbation and SALAC Both, Neither Exacerbation nor SALAC Neither) in 2001 on acute asthma exacerbations (hospitalization, emergency department visit, or short-term oral corticosteroid use) during 20022004 was assessed using logistic regression, adjusting for gender, age, health plan type, and region. Results. Of 11,779 patients, 8 were assigned to the EO group, 26 to SO, 12 to Both, and 54 to Neither in 2001. The incidence of exacerbations in 20022004 was higher for Both (61.8) versus EO (55.0) and for SO (37.3) versus Neither (31.9). The risk of exacerbation in 20022004 was increased significantly (p < .0001) for Both (3.394; 95 confidence interval CI 3.009, 3.827), EO (2.503; 95 CI 2.176, 2.879), and SO (1.277; 95 CI 1.166, 1.399) versus Neither. Conclusion. In this study, the risk of subsequent exacerbation was greatest in patients with both SALAC and acute asthma exacerbations, followed by those with exacerbations only and those with SALAC only. SO identified an additional 26 of asthma patients at increased risk for subsequent exacerbation. The results from this study demonstrate that SALAC indicators and a history of acute asthma exacerbations are independent predictors of future acute asthma exacerbations and highlight the important role of subacute asthma worsening in predicting and preventing future asthma exacerbations.
KW - Asthma
KW - Asthma control
KW - Asthma morbidity
KW - Exacerbations
KW - Managed care
UR - http://www.scopus.com/inward/record.url?scp=77953328493&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953328493&partnerID=8YFLogxK
U2 - 10.3109/02770901003605332
DO - 10.3109/02770901003605332
M3 - Article
C2 - 20528597
AN - SCOPUS:77953328493
SN - 0277-0903
VL - 47
SP - 422
EP - 428
JO - Journal of Asthma
JF - Journal of Asthma
IS - 4
ER -